Clinical Trial Update: A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease [Phase 2, Phase 3]

View source ↗

Summary

A randomized study to assess lenalidomide for active IgG4-related disease is in Phase 2 and Phase 3, and recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: IgG4 Related Disease | Phase 2, Phase 3 | Status: RECRUITING